Regeneron Pharmaceuticals (NASDAQ:REGN) underwent analysis by 19 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Insights from analysts’ 12-month price targets are revealed, presenting an average target of $1192.63, a high estimate of $1300.00, and a low estimate of $1000.00. Surpassing the previous average price target of $1120.63, the current average has increased by 6.42%. Deciphering Analyst Rating…